Bruton’s tyrosine kinase Inhibitors and Cardiotoxicity: More Than Just Atrial Fibrillation

PURPOSE OF REVIEW: The purpose of this review is to summarize the epidemiology, mechanisms, and management of cardiovascular complications of Bruton’s Tyrosine Kinase inhibitors (BTKIs). RECENT FINDINGS: Ibrutinib increases the risk of atrial fibrillation, bleeding, and hypertension compared with no...

Descripción completa

Detalles Bibliográficos
Autores principales: Sestier, Maude, Hillis, Christopher, Fraser, Graeme, Leong, Darryl
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Cardio-oncology (EH Yang, Section Editor)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330192/
https://www.ncbi.nlm.nih.gov/pubmed/34342738
http://dx.doi.org/10.1007/s11912-021-01102-1
_version_ 1783732653387677696
author Sestier, Maude
Hillis, Christopher
Fraser, Graeme
Leong, Darryl
author_facet Sestier, Maude
Hillis, Christopher
Fraser, Graeme
Leong, Darryl
author_sort Sestier, Maude
collection PubMed
description PURPOSE OF REVIEW: The purpose of this review is to summarize the epidemiology, mechanisms, and management of cardiovascular complications of Bruton’s Tyrosine Kinase inhibitors (BTKIs). RECENT FINDINGS: Ibrutinib increases the risk of atrial fibrillation, bleeding, and hypertension compared with non-BTKI therapies. The evidence to support an association between ibrutinib and other cardiovascular complications including ventricular tachyarrhythmias or cardiomyopathy is limited. Ibrutinib metabolism can be inhibited by some medications used to treat cardiovascular complications. The cardiovascular effects of more selective BTKIs, such as acalabrutinib, remain to be determined. SUMMARY: Future research should address the mechanisms underlying the cardiovascular complications of BTKIs and how best to manage them. The risks and benefits of more selective BTKIs as compared with ibrutinib require further evaluation.
format Online
Article
Text
id pubmed-8330192
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-83301922021-08-04 Bruton’s tyrosine kinase Inhibitors and Cardiotoxicity: More Than Just Atrial Fibrillation Sestier, Maude Hillis, Christopher Fraser, Graeme Leong, Darryl Curr Oncol Rep Cardio-oncology (EH Yang, Section Editor) PURPOSE OF REVIEW: The purpose of this review is to summarize the epidemiology, mechanisms, and management of cardiovascular complications of Bruton’s Tyrosine Kinase inhibitors (BTKIs). RECENT FINDINGS: Ibrutinib increases the risk of atrial fibrillation, bleeding, and hypertension compared with non-BTKI therapies. The evidence to support an association between ibrutinib and other cardiovascular complications including ventricular tachyarrhythmias or cardiomyopathy is limited. Ibrutinib metabolism can be inhibited by some medications used to treat cardiovascular complications. The cardiovascular effects of more selective BTKIs, such as acalabrutinib, remain to be determined. SUMMARY: Future research should address the mechanisms underlying the cardiovascular complications of BTKIs and how best to manage them. The risks and benefits of more selective BTKIs as compared with ibrutinib require further evaluation. Springer US 2021-08-03 2021 /pmc/articles/PMC8330192/ /pubmed/34342738 http://dx.doi.org/10.1007/s11912-021-01102-1 Text en © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Cardio-oncology (EH Yang, Section Editor)
Sestier, Maude
Hillis, Christopher
Fraser, Graeme
Leong, Darryl
Bruton’s tyrosine kinase Inhibitors and Cardiotoxicity: More Than Just Atrial Fibrillation
title Bruton’s tyrosine kinase Inhibitors and Cardiotoxicity: More Than Just Atrial Fibrillation
title_full Bruton’s tyrosine kinase Inhibitors and Cardiotoxicity: More Than Just Atrial Fibrillation
title_fullStr Bruton’s tyrosine kinase Inhibitors and Cardiotoxicity: More Than Just Atrial Fibrillation
title_full_unstemmed Bruton’s tyrosine kinase Inhibitors and Cardiotoxicity: More Than Just Atrial Fibrillation
title_short Bruton’s tyrosine kinase Inhibitors and Cardiotoxicity: More Than Just Atrial Fibrillation
title_sort bruton’s tyrosine kinase inhibitors and cardiotoxicity: more than just atrial fibrillation
topic Cardio-oncology (EH Yang, Section Editor)
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330192/
https://www.ncbi.nlm.nih.gov/pubmed/34342738
http://dx.doi.org/10.1007/s11912-021-01102-1
work_keys_str_mv AT sestiermaude brutonstyrosinekinaseinhibitorsandcardiotoxicitymorethanjustatrialfibrillation
AT hillischristopher brutonstyrosinekinaseinhibitorsandcardiotoxicitymorethanjustatrialfibrillation
AT frasergraeme brutonstyrosinekinaseinhibitorsandcardiotoxicitymorethanjustatrialfibrillation
AT leongdarryl brutonstyrosinekinaseinhibitorsandcardiotoxicitymorethanjustatrialfibrillation

Ejemplares similares